Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

BACKGROUND: Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the efficacy and safety of MSCs combined with basiliximab and calcineurin inhibitor as second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ke, Lin, Ren, Fan, Zhiping, Chen, Xiaoyong, Wang, Yu, Huang, Fen, Xu, Na, Zhang, Xi, Zhang, Xin, Xuan, Li, Wang, Shunqing, Lin, Dongjun, Deng, Lan, Nie, Danian, Weng, Jianyu, Li, Yonghua, Zhang, Xiaohui, Li, Yuhua, Xiang, A. P., Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900437/
https://www.ncbi.nlm.nih.gov/pubmed/35255929
http://dx.doi.org/10.1186/s13045-022-01240-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900437/
https://www.ncbi.nlm.nih.gov/pubmed/35255929
http://dx.doi.org/10.1186/s13045-022-01240-4

Ejemplares similares